Rehab Expert: Pain Patients Denied Needed Opioids in Palliative Care

http://www.painmedicinenews.com/Policy-and-Management/Article/12-17/Rehab-Expert-Pain-Patients-Denied-Needed-Opioids-in-Palliative-Care/45403#_=_

David, a 38-year-old father of four and five-year survivor of fungal meningitis, experiences the long-term effects of contaminated epidural injections that have left him with headaches, visual disturbances, tinnitus, adhesive arachnoiditis and fibromyalgia.

His story exemplifies the gap between state and federal health care laws and treatment protocols for those with chronic pain requiring high-dose opioid therapy, wrote Terri Lewis, PhD, in “States of Pain: Part II. The Influence of Regulations” in National Pain Report.

“High-dose opiates—depending on the document, set of guidelines and law you’re looking at—are now being unilaterally redefined as addiction,” said the rehabilitation and mental health educator and clinician from Nashville, Tenn. “Our interactions with the care system are built on a scaffold of law, regulation, policy, professional practices, insurance regulations, guidelines and personal resources. This scaffold is destabilizing across the system as new guidelines and reactive public responses to increasing opioid-associated overdoses seize the public imagination.”

Dr. Lewis cited a conflict between the Controlled Substances Act, which classifies opioids as a Schedule II narcotic, and the Drug Enforcement Administration (DEA).

“The driver is rooted in DEA policy in managing Schedule II narcotics and comingling this activity with interdiction of illegal distribution to the streets,” she explained. “The DEA will claim they do not tell individuals how to practice. But they do influence choices about what is being done to treat at the local level by the thrust of current prosecutions.”

“It’s not so much classification of opioids as Schedule II substances as [it is] state laws and guidelines governing who can prescribe them, when and how that may pose a barrier to managing chronic pain,” said Joe Rotella, MD, chief medical officer, American Academy of Hospice and Palliative Medicine. “Because of a shortage of palliative medicine and pain specialists, many people with chronic pain receive care solely from a primary care provider.”

Larry Driver, MD, who sits on the professional education committee and chairs the CME oversight committee for the American Academy of Pain Medicine, agreed, stating, “We certainly need more physicians and other health care professionals who can provide appropriate and safe pain management and palliative care. This includes being aware of patients at risk for medication misuse or abuse and potential addiction, and taking steps to mitigate those risks while caring for the patient.”

Indeed, said Dr. Lewis, “we need more physicians trained in family medicine, physiatry, neurology, pain management and allied health practitioners. We need designated, mandatory medical home programs located within physician practices in every state, and every insurer to reimburse for palliative, medical home and integrated treatment. Guidance, issued by the Federation of State Medical Boards, needs to be rewritten; and every state pain regulation ought to contain consistent, unifying language to distinguish acute from palliative and hospice pain care.”

She added that conflating addiction prevention within palliative and hospice care must be modified, so physicians can “treat the whole person.”

“It’s critical to elevate knowledge of appropriate prescribing of controlled substances across various providers and specialties,” Dr. Rotella said. “Today, there is little to no curricula on managing pain in medical and nursing schools.”

He pointed out that the Palliative Care and Hospice Education and Training Act, a bipartisan bill, “would expose medical students, nursing students, pharmacy students and social work students to palliative care education and training early on to develop skills in assessing and managing pain and evidence-based prescribing. Palliative care focuses on care coordination. So, expanding these skills can play a role in stemming opioid misuse.”

How fentanyl gets to the U.S. from China

How fentanyl gets to the U.S. from China

https://news.vice.com/en_us/article/j5vpdx/how-fentanyl-gets-to-the-us-from-china

The powerful synthetic opioid fentanyl is now the deadliest drug in America, causing an estimated 19,000 fatal overdoses in 2016.

The DEA says most of the illicit fentanyl comes from China, either shipped directly to U.S. consumers through the mail or mixed with heroin that is smuggled across the southern border by Mexican drug cartels.

At New York City’s JFK airport, the point of entry for about 60 percent of the country’s international mail packages, seizures of fentanyl by Customs and Border Protection agents increased from 7 in 2016 to 84 in 2017. All of the packages came from China. Nationwide, fentanyl seizures by CBP increased from 459 pounds in 2016 to 1,296 pounds last year.

In New York City, the DEA seized a record 193 kilos of fentanyl in 2017 — enough to kill the city’s population 11 times over. James Hunt, special agent in charge of the DEA’s New York field division, said it’s virtually impossible to stop the flow of fentanyl.

“The southwest border of the United States is porous,” Hunt said. “There’s thousands of miles of border. Thousands of trucks stop every day at the border. There’s millions and millions of parcels coming into the country every day, you can’t search them all. And traffickers know that.”

Jeff Sessions Leaves the Cole Memo Intact, For Now

https://www.leafly.com/news/politics/jeff-sessions-leaves-the-cole-memo-intact-for-now

Late Thursday, US Attorney General Jeff Sessions formally rescinded 25 guidance documents created by his predecessors at the Justice Department. The guidance memos, meant to set policy and establish enforcement priorities, dealt with a variety of issues. Most critically for the cannabis industry, the Cole memo was not among the 25 memo scuttled by Sessions.

 

By leaving the Cole memo intact, Sessions allowed state-legal adult cannabis to stand. For the time being.

That means the Justice Department’s Aug. 2013 guidance document, which spelled out the DOJ’s priorities and areas of concern regarding legal adult-use cannabis in Colorado and Washington (and all later adult-use states), remains intact at least for the foreseeable future.

The Cole memo, written by James Cole, a deputy attorney general under then-AG Eric Holder, spelled out the conditions under which the Justice Department would allow states to regulate and enforce their own cannabis laws. The memo did not federally legalize cannabis, or legally prevent the DEA or other Justice Department agencies from enforcing federal cannabis laws in legal states. It is merely a policy document meant to guide departmental decisions about state-legal cannabis.

RELATED STORY
The Cole Memo: What Is It and What Does It Mean?

Sessions, a vocal opponent of state legalization laws, has often expressed a desire to reverse two decades of progress won by legalization advocates. Rescinding the Cole memo would have been the most direct attack on those gains. In his move on Thursday, Sessions did not eliminate the Cole guidance, but neither did he confirm that it would continue to guide his department’s decisions.

In March, President Trump issued Executive Order 13777, which called for agencies to establish Regulatory Reform Task Forces to identify existing regulations for potential repeal, replacement, or modification. The Department of Justice Task Force, chaired by Associate Attorney General Rachel Brand, began its work in May.

On November 17, Sessions issued a memorandum prohibiting DOJ components from using guidance documents to circumvent the rulemaking process and directed Associate Attorney General Brand to work with components to identify guidance documents that should be repealed, replaced, or modified.

RELATED STORY
Sessions Calls Cole Memo ‘Valid,’ Says Fed Resources Are Limited

The DOJ’s media release stated that the Department “is continuing its review of existing guidance documents to repeal, replace, or modify.” So the Cole memo could still be under review. 

The list of 25 guidance documents that DOJ withdrew on Thursday are listed below. For more detail, see the Justice Department’s web site

  1. ATF Procedure 75-4.
  2. Industry Circular 75-10. 
  3. ATF Ruling 85-3. 
  4. Industry Circular 85-3. 
  5. ATF Ruling 2001-1. 
  6. ATF Ruling 2004-1.
  7. Southwest Border Prosecution Initiative Guidelines (2013).  
  8. Northern Border Prosecution Initiative Guidelines (2013).  
  9. Juvenile Accountability Incentive Block Grants Program Guidance Manual (2007). 
  10. Advisory for Recipients of Financial Assistance from the U.S. Department of Justice on Levying Fines and Fees on Juveniles (January 2017). 
  11. Dear Colleague Letter on Enforcement of Fines and Fees (March 2016). 
  12. ADA Myths and Facts (1995).
  13. Common ADA Problems at Newly Constructed Lodging Facilities (November 1999).
  14. Title II Highlights (last updated 2008).
  15. Title III Highlights (last updated 2008).
  16. Commonly Asked Questions About Service Animals in Places of Business (July 1996).
  17. ADA Business Brief: Service Animals (April 2002). 
  18. Prior Joint Statement of the Department of Justice and the Department of Housing and Urban Development Group Homes, Local Land Use, and the Fair Housing Act (August 18, 1999). 
  19. Letter to Alain Baudry, Esq., with standards for conducting internal audit in a non-discriminatory fashion (December 4, 2009). 
  20. Letter to Esmeralda Zendejas on how to determine whether lawful permanent residents are protected against citizenship status discrimination (May 30, 2012). 
  21. Common ADA Errors and Omissions in New Construction and Alterations (June 1997). 
  22. Common Questions: Readily Achievable Barrier Removal and Design Details: Van Accessible Parking Spaces (August 1996). 
  23. Website guidance on bailing-out procedures under section 4(b) and section 5 of the Voting Rights Act (2004).  
  24. Americans with Disabilities Act Questions and Answers (May 2002).
  25. Statement of the Department of Justice on Application of the Integration Mandate of Title II of the Americans with Disabilities Act and Olmstead v. L.C. to State and Local Governments’ Employment Service Systems for Individuals with Disabilities (October 31, 2016).

Indiana Couple Wins First Xarelto Trial in Philadelphia

http://pittsburgh.legalexaminer.com/fda-prescription-drugs/indiana-couple-wins-first-xarelto-trial-in-philadelphia/

On December 5, 2017, an Indiana couple won their Xarelto lawsuit in Philadelphia. The jury ordered that the drug manufacturers, Bayer AG and Johnson & Johnson (J&J), pay $27.8 million for failing to warn about the blood-thinner’s serious side effects.

Of that award, $1.8 million was designated for compensatory damages and $26 million in punitive damages. This is the first loss for the manufacturers in the Xarelto litigation. The first three federal bellwether trials resulted in defense verdicts.

Indiana Couple Win First Xarelto Trial in Philadelphia Mass Tort

The couple in the Pennsylvania state court case filed their Xarelto lawsuit in 2015, claiming that the wife was first prescribed Xarelto in 2013 to prevent a stroke and took it for about a year. Then in June 2014, she developed gastrointestinal bleeding and had to be hospitalized. She blamed Xarelto for her injuries and claimed that the manufacturers didn’t do enough to warn of the drug’s potential dangers.

This was one of about 1,400 cases pending in the Pennsylvania state court mass tort litigation in Philadelphia, and the first to go to trial in that litigation. The trial was briefly delayed because of allegations that sales representatives from Janssen Pharmaceuticals, a subsidiary of J&J, met with the plaintiffs’ doctor. The meeting allegedly resulted in a change in the doctor’s testimony.

During the trial, a former FDA commissioner testified that the Xarelto label did not have adequate warnings about its side effects. Bayer and J&J have stated that they plan to appeal the verdict.

Federal Trials Have Been Favoring Defendants

In August 2017, in the third case to go to trial in the Xarelto Multidistrict Litigation (MDL) pending in federal court a Jackson, Mississippi jury determined that the manufacturers of Xarelto were not liable. The plaintiff in that case claimed she suffered serious gastrointestinal bleeding just a month after she started taking Xarelto to prevent blood clots.

Like thousands of other plaintiffs in the Xarelto litigation, she claimed that the drug manufacturers failed to adequately warn about Xarelto’s bleeding risks.

If they had, she claims that she could have avoided her injuries. Her case was one of over 19,000 that are currently pending in the Xarelto MDL, which is pending in the U.S. District Court for the Eastern District of Louisiana.

Xarelto Lacks Antidote for Bleeding

 

Xarelto and other newer-generation anticoagulant drugs have no readily available antidote to stop excessive bleeding once it starts.

Whereas patients taking warfarin, the leading blood-thinner for years, can be treated with vitamin K injections, which encourage the blood to begin clotting again, patients taking Xarelto have no such recourse. Patients simply have to wait for Xarelto to flush out of their system. This makes any bleeding events significantly more dangerous and potentially deadly.

TX: doctors filed a class action suit against the narcotics bureau for practicing medicine without a license and the doctors won.

I found out today it’s is the MS Bureau of Narcotics that are pressuring the doctors in this state to cut back. In TX they did the same thing and the doctors filed a class action suit against the narcotics bureau for practicing medicine without a license and the doctors won. After Christmas I’m going to attempt to file a criminal charge against the director of MBN. The doctors here are to scared to do it. I’ve also spoken to the DEA. They are trying to shut down the pill mills but they are NOT interfering with doctors prescribing for real causes like my nerve damage. I’m medically retired Law Enforcement. I don’t mind stirring up a stink when they start messing with my quality of life. Check in your state. Most states have similar laws.The MBN does not have a medical doctor on staff.

More “assisted suicide” by our medical system

My father who was also a physician took his own life because of trigeminal neuralgia. Four days ago a long term friend and former and a former patient of mine shot himself in the head when he was forced by the medical board to taper off the opioids that were keeping him comfortable enough to work productively.

Refusal to fill: is “I’m not comfortable” being replaced with “I don’t have stock” ?

The “excuse” … “I’m not comfortable” infers that the Pharmacist has made a decision… based on certain FACTS that would make the prescription not medically appropriate for a particular pt.  Level one interaction with the pt’s other medications, allergy, dose too high or too low.. having checked a PMP report the pt appears to be a doc/pharmacy shopper…

The “excuse” ….”I don’t have inventory” .. is a fact that supposedly doesn’t have anything associated with a professional medical decision.  I suspect that most pharmacists believe that in saying that.. there is no way for the pt to prove that the pharmacy has – or has not – any inventory.

I was at a meeting of the FL board of Pharmacy in June of 2015 when they were discussing a new regulation about how Pharmacists in FL are suppose to NOT start looking for reason to refuse to fill a controlled prescription.  It went into effect the end of Dec 2015.  At that meeting a chronic pain doctor asked the attorney for the board if a pharmacist lying to a pt about having inventory was UNPROFESSIONAL CONDUCT…. and basically the response from the Board’s attorney was “.. there is nothing in the practice act that addresses that … so NO …”

After all the DEA cut opiate production quotas by up to 25% in 2017 and proposed another 20% cut in 2018.  The largest pharmacy wholesaler ( McKesson) had the DEA try to build a case against them for not properly controlling the distribution of opiates and prepared to hit them with a ONE BILLION DOLLAR FINE… but apparently McKesson hired the baddest ass attorney firm in the country and the DEA attorneys became unsure of their “slap dunk case” against McKesson and every settle with McKesson paying a few million in fines..  But there were two other major pharmacy wholesalers which the DEA  was probably going after next after they “took down Mc Kesson”… remember the DEA’s budget is TWO BILLION… so a BILLION more from McKesson would have allowed them to do what ?

So, I would expect that the pharmacy wholesalers are going to “tighten down” on what they will allow any particular pharmacy to purchase.

So what is a pt to do?… get use to the “pharmacy crawl” ?

Most pt don’t know that each pharmacy is required to keep a PERPETUAL INVENTORY on all C-II…  They should be able to go to their perpetual inventory book and know exactly what is on hand at any moment. Each prescription filled is entered into this record by date and maybe by the time the label of the prescription was printed… also they have to enter into this perpetual inventory any increase in inventory when they receive it from their supplier.

The pt should at the very least have someone go with them to witness that the reason that your prescription was not filled was because it was stated that they had no inventory… at least take a picture of the Rx dept staff that told you “NO INVENTORY” or if legal.. video the transaction.

The only option that the pt has at this point is to hire an attorney to ask the courts to subpoena the pharmacy’s inventory records for the particular day and the particular medication to validate that there was no inventory on hand… when you presented a prescription to be filled.

Proving that there was medication on hand… and chronic pain pt or any pt suffering from a subjective disease should be considered disabled and discriminating against a person covered by the Americans with Disability Act and/or Civil Rights Act… that discrimination is considered a CIVIL RIGHTS VIOLATION.

Once a pt has proven that they have been lied to and discriminated against… the Pharmacist and maybe their employer no longer has the UPPER HAND !

 

An Invitation from Art Levine, reporter for Newsweek and other major media outlets

An Invitation from Art Levine, reporter for Newsweek and other major media outlets:

Art Levine is a freelance journalist who has written for Newsweek on the deadly, damaging effects of the crackdown on legal opioid prescribing to chronic pain patients. See  http://www.newsweek.com/va-opiod-policy-wreaks-havoc-former-marine-683467 and https://www.alternet.org/drugs/pundits-focused-trump-craziness-ignoring-threat-mentally-ill-addicts

Art hopes to interview surviving family members or friends of chronic pain patients who have committed suicide, since 2016 and the CDC guidelines — and who had no history of major mental illnesses prior to developing their chronic pain.

Art can be reached via twitter @ArtL7, or facebook PM messaging and https://www.facebook.com/ArtLDC. He is interested in interviewing one or two more chronic pain patients concerning your personal knowledge, of cases where you or other patients who have no histories of addiction or drug abuse, are being denied opioids or have been discharged by their doctors. He also looking for a few examples of doctors who haven’t yet been arrested,  aren’t being subsidized  by drug companies or hadn’t had their licenses revoked but are still being harassed or otherwise threatened by enforcement /regulatory agencies because they’re prescribing opioids to chronic or acute pain or cancer patients. (He can’t use the Dr. Tennant case, for instance, because of Dr. Tennant’s ties to the controversial Insys company facing criminal indictment http://www.cnn.com/2017/09/06/politics/insys-cancer-drug-company-faked-cancer-patients-to-sell-drug/index.html, which doesn’t make him credible to his editors.)

He is  also looking for people with policy knowledge about specific regulatory, legal, DEA developments in such states as Indiana and Maine.

I (RICHARD LAWHERN/Steve Ariens) will be available to hear about your experiences with Mr. Levine during interviews. I have cautioned him that he will be dealing with people who have already been traumatized by pain or deep emotional loss. He has promised to interview thoughtfully and to represent your stories without distortion when he publishes.

Regards all,
Red Lawhern/ Steve Ariens

 

Art Levine 202-248-9320 / cell phone: 202-557-8443 Please reply directly to this Yahoo mail address but also please  CC: to my gmail account, artslevine@gmail.com, due to occasional Yahoo mail glitches.

 

 

Life expectancy in the U.S. is falling — and drug overdose deaths are soaring

Women attend a candlelight vigil during the FED UP! Coalition’s annual International Overdose Awareness Day event in Washington in August. A new CDC report ESTIMATES 63,600 people died of drug overdoses in 2016.

What good is the CDC, if all they can do is ESTIMATE STATS ?

www.statnews.com/2017/12/21/life-expectancy-drug-overdose

Life expectancy in the U.S. has fallen for the second year in a row, the first time it’s dropped for two consecutive years in more than half a century.

People born in the U.S. in 2016 could expect to live 78.6 years on average, down from 78.7 the year before, according to a new report released Thursday by the Centers for Disease Control and Prevention. The most common cause of death: heart disease.

The report also found death rates — calculated from the number of deaths per 100,000 people — actually rose among young adults between 2015 and 2016. And while the authors didn’t draw a direct link, another report also released Thursday by the CDC found an estimated 63,600 people died of drug overdoses in 2016. Two-thirds of those deaths were caused by opioids. Adults between the ages of 25 and 54 had the highest rate of drug overdose death.

Here’s a look at the findings:

Most common causes of death

Heart disease was the leading cause of death, followed by cancer, unintentional injuries, chronic lower respiratory diseases, stroke, Alzheimer’s disease, diabetes, influenza and pneumonia, kidney disease, and suicide.

One key point: Unintentional injuries climbed to the third leading cause of death in 2016, swapping spots with chronic lower respiratory diseases. It’s worth noting that most drug overdose deaths are classified as unintentional injuries.

AS IF… NO ONE would use drugs – including ALCOHOL to commit SUICIDE ?

The most common causes of death

Cause of death Percent
Heart disease 23.1
Cancer 21.8
Unintentional injuries 5.9
Chronic lower respiratory disease 5.6
Stroke 5.2
Alzheimer’s disease 4.2
Diabetes 2.9
Flu and pneumonia 1.9
Kidney disease 1.8
Suicide 1.6
 
They kind of left out the 250,000 – 400,000 deaths from medical errors
Megan Thielking / STAT. Source: Mortality in the United States, 2016. National Center for Health Statistics.

Black men are dying at alarmingly high rates

Life expectancy isn’t falling for women — just for men. Life expectancy for women at birth is 81.1 years, compared to 76.1 years for men.

The death rate for the general population actually declined slightly in 2016, but that drop wasn’t seen across all racial and ethnic groups. Death rates among black men climbed 1 percent in 2016, while death rates among white women actually fell 1 percent. There weren’t any big changes in death rates among black women, white men, or Hispanic men or women.

Age-adjusted death rates

Group Age-adjusted death rate
General population 728.8
Black men 1,081.2
Black women 734.1
White men 879.5
White women 637.2
Hispanic men 631.8
Hispanic women 436.4
 
Megan Thielking / STAT. Source: Mortality in the United States, 2016. National Center for Health Statistics.

Drug overdose deaths continue to climb

Drug death rates are increasing much faster than they have in recent years. Overdose death rates climbed roughly 10 percent per year between 1999 and 2006. Then there was a relative lull: Between 2006 and 2014, they increased roughly 3 percent each year.

But from 2014 to 2016, death rates tied to drug overdoses jumped 18 percent each year.

Overdose deaths have climbed among all age groups

Year 15 to 24 25 to 34 35 to 44 45 to 54 55 to 64 65 and older
1999 3.2 8.1 14 11.1 4.2 2.7
2000 3.7 7.9 14.3 11.6 4.2 2.4
2001 4.2 8.6 15.5 13 4.7 2.6
2002 5.1 10.5 18.1 16.2 6 3
2003 6 11.4 18.9 17.9 6.9 3
2004 6.6 11.9 19.3 19.3 7.8 3
2005 6.9 13.6 19.6 21.2 9 3.3
2006 8.1 16.1 21.7 24.1 10.5 3.6
2007 8.2 16.8 21.4 25.1 12.2 3.8
2008 8 16.8 21.1 25.2 12.9 4.1
2009 7.7 17.2 20.5 25.4 13.7 4.3
2010 8.2 18.4 20.8 25.1 15 4.3
2011 8.6 20.2 22.5 26.7 15.9 4.6
2012 8 20.1 22.1 26.9 16.6 4.9
2013 8.3 20.9 23 27.5 19.2 5.2
2014 8.6 23.1 25 28.2 20.3 5.6
2015 9.7 26.9 28.3 30 21.8 5.8
2016 12.4 34.6 35 34.5 25.6 6.2
 
Megan Thielking / STAT. Source: Drug Overdose Deaths in the United States, 1999–2016. National Center for Health Statistics.

Deaths due to synthetic opioids are rising

The rate of overdose deaths involving synthetic opioids other than methadone — a category that includes fentanyl, fentanyl analogs, and tramadol — doubled between 2015 and 2016. The rate of drug overdose deaths involving natural and semisynthetic opioids, such as oxycodone and hydrocodone, also rose, while overdoses involving methadone declined.

The opioids most commonly involved in overdose deaths
Type of opioid 2015 2016
Any opioid 33,091 42,249
Heroin 12,989 15,469
Natural and semisynthetic 12,727 14,487
Methadone 3,301 3,373
Other synthetic opioids 9,580 19,413
63,600 deaths from DRUG OVERDOSES… but only 42,249 from all opiates – 33% of total estimated deaths from NON-OPIATES  and a lot of LUMPING TOGETHER of the causes of deaths ?
Megan Thielking / STAT. Source: Drug Overdose Deaths in the United States, 1999–2016. National Center for Health Statistics.

 

 

Medical regulator assures opioid rule changes won’t throw patients ‘to the wolves’

http://www.clarionledger.com/story/news/politics/2017/12/15/medical-regulator-assures-opioid-rule-changes-dont-throw-patients-wolves/955257001/

Susan Norton of Brookhaven attended the Mississippi State Board of Medical Licensure meeting Friday, actively withdrawing from morphine.

Norton, who has been diagnosed with a chronic, painful bladder disease called Interstitial cystitis, was discharged from her pain management specialist in November, just as the state’s medical regulatory agency started mulling increased opioid prescription rules.

“I just feel like the state of Mississippi has thrown me to the wolves and literally to the street to figure this out on my own, and I don’t want to die. But there’s no where to land,” Norton said, just after

board members said their rule changes would not prohibit all opioid use for chronic pain.

“What I’m hearing today is not what’s happening out there with patients like me who have legitimate pain and need something … The doctors are scared.”

Board members assured Norton their

proposed opioid prescription rule changes do not prevent a doctor from prescribing opioids to treat the pain associated with her condition

but that they would require doctors to complete additional documentation. 

 

“If asking someone to jump through a few extra hoops prevents a physician from doing that … shame on them,” said board member Dr. Randy Easterling.

Norton had been on 60 milligrams of morphine and 12 milligrams of Dilaudid for 10 years but she’s been cut off the last five weeks, causing her to experience withdrawals. She said she can see her heart beating through her chest sometimes. 

“It’s where you just lay on the cold bathroom floor just to feel something other than pain,” Norton said.

Norton was near finishing nursing school 20 years ago when she was diagnosed with the bladder disease, which changed her life. Opioid users are sometimes labeled “drug seekers,” Norton noted, but she’s tried other pain management techniques with little success.

 “If it was Tylenol and that worked I would be so happy, but sometimes it’s going to be more than that,” she said to the board.

In an open work session Friday, the medical licensure board finalized and unanimously passed proposed opioid prescription rule changes, tweaked slightly since its last hearing and pending additional review.

The regulations limit opioid prescriptions to seven days for acute pain, prohibit opioids for chronic pain except where doctors can document it’s the only viable option and require doctors to check the Prescription Monitoring Program and deliver drug tests to patients before writing opioid prescriptions. 

The rules do not apply to terminal and cancer pain patients or opioid use in an inpatient setting. The changes are aimed at ramping up prescription monitoring and

discouraging doctors from prescribing opioids

amid an epidemic that kills nearly 100 Americans a day.

“It’s scary,” Norton said of not having access to her medication. “I just feel like I just got thrown out because it was too much for the doctors to want to have to deal with it.”

“Unfortunately, all the doctors won’t read this …

We’re not stopping opioids. We’re not doing anything like that. We’re just for the responsible use

” said board president Dr. Charles Miles, who cites medical literature about the ineffectiveness of opioids for the management of long-term pain. “You can take opioids to the point that the opioid itself causes the pain. It’s ‘opioid hyperalgesia’ and you don’t know that until you start backing off the opioids. then the pain gets better.”

Board members didn’t agree on everything in the nearly three-hour meeting Friday, during which they negotiated mostly specific, technical changes to the language of the new rules.

Board member Dr. Ken Lippincott, a psychiatrist, raised concerns over patient drug testing requirements in psychiatric offices when the patient is being prescribed benzodiazepines, like Valium or Xanax. Some smaller clinics might not have the facilities to do drug testing and, more concerning, it could damage trust between the physician and patient, Lippincott said.

Board member Dr. Claude Brunson, a University of Mississippi Medical Center physician, called for the board to vote whether to exempt psychiatrists from the new rule, saying it may do more harm than intended good.

“If that’s going to deter folks from getting mental help that they need, that’s a public issue,” Brunson said.

The motion failed.

The new rules will go to the Occupational Licensing Review Commission, which the Legislature created during the 2017 session to reign in regulatory boards, for final approval. First, the proposed changes must be filed with the secretary of state’s office to allow for public comment.

Apparently these board members do not listen to what they say or what is put in the proposed regulations.. They are not going to prohibit opiates being prescribed for chronic pain.. BUT.. the prescribers are going to be presented with a whole lot of time consuming administrative tasks in order to do so.. with apparently NO GUARANTEE that in doing so would indemnify the prescriber from being “drug thru the mud” for doing so ?

RULE CHANGES are always subject to interpretation and all too often the interpretation of the rule that is enforced may not meet the letter and intent of the rule.

Just look at what the DEA has done over the last 47 yrs with interpretations of the Controlled Substance Act 1970 and they have generated some NEW INTERPRETATIONS of that law in the last yr +.